Insight on USFDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor
Posted on29 Nov 2018
Comments0
The U.S. Food and Drug Administration (FDA) today approved Vitrakvi® (larotrectinib), the first ever oral TRK inhibitor, for the treatment of adult... Read More
Case Study: Pfizer’s Lyrica’s patent extension with paediatric exclusivity
USFDA granted 6-month pediatric exclusivity to Lyrica, which helps to Lyrica to extent the patent expiration by additional 6 month. Lyrica received... Read More
What is pediatric exclusivity?
Posted on29 Nov 2018
Comments0
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and may run concurrently with a patent but... Read More
Case Study: Insight on DRL-Indivior Suboxone Patent Battle
June 2018 : DRL got the generic approval for Suboxone Dr Reddy’ s Laboratories received approval from the USFDA for generic version... Read More
Grünenthal entering into US market with acquisition of US based Averitas Pharma
Grünenthal has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be... Read More
Insight on Strides – SUDA Pharma Strategic Deal
Strides Pharma Science’s wholly owned subsidiary, Strides Pharma Global Pte Limited, Singapore has entered into an exclusive product development, licensing and supply... Read More
How much is the ideal royalty payment in pharmaceutical industry?
A royalty payment is made to the legal owner of the property, patent, copyrighted work, or franchise by licensees or franchisees who... Read More
Pharma acquisition Insight: Hikma Pharmaceuticals to acquire Medlac Pharma
Hikma Wednesday said it had a deal to buy Medlac Pharma Italy Co., a Vietnamese injectables manufacturing company established a decade ago... Read More
Glenmark’S Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea for Ophthalmic Solution Products
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced it has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. Ltd.... Read More
Novartis R&D portfolio update
Posted on06 Nov 2018
Tagsbrolucizumab, canikinumab, cosentyx, crizanlizumab, Entresto, Gilenya, novartis, NSCLC, ofatumumab, R&D portfolio
Comments0
Novartis took strong action to focus the company and its capital towards the Innovative Medicines Division, resulting in an industry leading pipeline.... Read More